Acorda again submits Fampridine-SR for U.S. approval

04/23/2009 | Reuters

Acorda Therapeutics resubmitted its multiple sclerosis drug Fampridine-SR for FDA approval a month after the agency rejected the application because of "format issues." Analysts expect the agency to accept the filing by late June and hand down a decision in February.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI